Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases (Q26778600)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases	scientific article

Statements

scholarly article

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases (English)

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Alejandro Souto

1

0 references

José Ramón Maneiro

2

0 references

Juan J Gómez-Reino

3

0 references

language of work or name

0 references

publication date

March 2016

0 references

0 references

55

0 references

3

0 references

523-34

0 references

Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Biologic registries in rheumatology: lessons learned and expectations for the future.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

The role of drug and disease registries in rheumatic disease epidemiology

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Communicating and promoting comparative-effectiveness research findings

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Methods for comparative effectiveness research/patient-centered outcomes research: from efficacy to effectiveness

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Inequities in access to biologic and synthetic DMARDs across 46 European countries

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: a nationwide population-based cohort study

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

The utility of administrative data for measuring adherence to cancer surveillance care guidelines

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Ten years with biologics: to whom do data on effectiveness and safety apply?

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Incidence and predictors of secondary fibromyalgia in an early arthritis cohort

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Pain and joint mobility explain individual subdimensions of the health assessment questionnaire (HAQ) disability index in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

21 January 2018

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population-based cohort study

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEV374

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1093/RHEUMATOLOGY/KEV374

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26778600&oldid=1500296045"